EECP Treatment Advantages and Disadvantages

Enhanced external counterpulsation (EECP) is a mechanical form of treatment for angina. While several clinical studies appear to show that this treatment can be helpful in reducing symptoms of angina in patients with coronary artery disease (CAD), EECP has yet to be accepted by most cardiologists and has not entered the mainstream of cardiology practice.

EECP is a mechanical procedure in which long inflatable cuffs (like blood pressure cuffs) are wrapped around both of the patient’s legs. While the patient lies on a bed, the leg cuffs are inflated and deflated synchronously with each heartbeat.

The inflation and deflation are controlled by a computer, which uses the patient’s electrocardiogram (ECG) to trigger inflation early in diastole (when the heart relaxes and is filled with blood), and deflation just as systole (heart contraction) begins. The inflation of the cuffs occurs sequentially, from the lower part of the legs to the upper, so that the blood in the legs is “milked” upwards, toward the heart.

EECP has at least two potentially beneficial actions on the heart. First, the milking action of the leg cuffs increases the blood flow to the coronary arteries during diastole. (The coronary arteries, unlike other arteries in the body, receive their blood flow in between heartbeats, instead of during each heartbeat.)

Second, by its deflating action just as the heart begins to beat, EECP creates something like a sudden vacuum in the arteries, which reduces the work the heart muscle has to perform in pumping blood. It is also speculated that EECP may help reduce endothelial dysfunction.

It has been speculated that EECP improves peripheral arterial function, which serves to reduce myocardial oxygen demand.

Several studies suggest that EECP can be quite effective in treating chronic stable angina. A small randomized trial showed that EECP significantly improved both the symptoms of angina (a subjective measurement) and exercise tolerance (a more objective measurement) in patients with CAD. EECP also significantly improved “quality of life” measures, as compared to placebo therapy. Other studies have shown that the improvement in symptoms following a course of EECP seems to persist for up to five years (though 1 in 5 patients may require another course of EECP to maintain their improvement).

The mechanism for the apparent sustained benefits seen with EECP is unknown. There is some evidence suggesting that EECP can help induce the formation of collateral vessels in the coronary artery tree, by stimulating the release of nitric oxide and other growth factors within the coronary arteries.

There is also evidence that EECP may act as a form of “passive” exercise, leading to the same sorts of persistent beneficial changes in the autonomic nervous system that are seen with real exercise.

EECP can be somewhat uncomfortable but is generally not painful. In studies, the large majority of patients have tolerated the procedure quite well.

But not everyone can have EECP. People probably should not have EECP if they have aortic insufficiency, or if they have had a recent cardiac catheterization, an irregular heart rhythm such as atrial fibrillation, severe hypertension, peripheral artery disease involving the legs, a congenital heart defect, hypertrophic cardiomyopathy, valvular disease, an enlarged heart, a pacemaker, pulmonary hypertension, a heart rate over 120 beats per minute, or a history of deep venous thrombosis. For anyone else, however, the procedure appears to be safe.

Based on what we know today, EECP should be considered in anybody who still has angina despite maximal medical therapy, and in whom stents or bypass surgery are deemed not to be good options. Medicare has approved coverage for EECP for patients with angina who have exhausted all their other choices.

In general, the cardiology community has largely chosen to ignore such an unconventional form of therapy, and many cardiologists fail to even consider offering EECP as a therapeutic option. Consequently, most patients who have angina never hear about it.

Still, when a noninvasive treatment for angina exists that is safe and well-tolerated, when available evidence (as imperfect as it may be) strongly suggests the treatment is quite effective in many patients, and when the patient being treated will be able to tell pretty definitively whether or not the treatment has helped in their own individual case (by the presence or absence of a substantial reduction in angina symptoms), it does not seem unreasonable to allow patients with stable angina to opt for a trial of that noninvasive therapy, perhaps even before they are pushed into invasive therapy.

If you are being treated for stable angina and still have symptoms despite therapy, it is entirely reasonable for you to bring up the possibility of trying EECP. Your doctor should be quite willing to discuss this possibility with you, objectively and without prejudice.